Treatment of Advanced Metastatic Thymic Carcinoid: Typical Histology, SRI-Positive, Slowly Progressing
This protocol addresses first-line management of advanced or metastatic carcinoid tumor of the thymus presenting as typical carcinoid — or disease that is radiologically slow to progress — with confirmed somatostatin receptor imaging positivity and no atypical or significantly progressive features.
Clinical Scenario
- Advanced or metastatic thymic carcinoid
- Typical carcinoid histology, or slowly progressing on imaging
- Somatostatin receptor imaging (SRI)-positive
- No atypical or significantly progressive features
Treatment Approach
When somatostatin receptor imaging confirms adequate uptake across evaluable lesions, a receptor-targeted radionuclide therapy is among the options considered in this setting. Full selection criteria, the complete set of treatment options, and sequencing guidance are available in the structured protocol.
References
DOI: 10.1016/j.annonc.2021.01.003
- SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]
- PRRT (based on positive uptake at SRI on all RECIST-evaluable targets) as alternative second-line (in case of uncontrolled CS) or mainly third-line therapy (beyond SSAs and or everolimus) in morphologically progressive or high tumour burden advanced LC and ThCs is recommended [IV, B]
- IFN-a as a potential second-line (in case of uncontrolled CS) or mainly third-line alternative (beyond SSAs and or everolimus) is recommended in morphologically progressive or high tumour burden advanced LC and ThCs [IV, B]
View source ↗